Lets talk qualitative results, what stood out for me.
Growth in FDF, this is where the major earnings will come from in the near term (1-2 years)
Healthy 21% QoQ growth even though they are building a lot more capacities.
Synthesis
Growth area for medium term.
95% YoY growth but the base is lower.
The only have 4 commercial products.
While the active projects stand at 50.
When those 46 get commercialized, this will be the main growth engine of the company.
Laurus Bio
1% of the Revenue Pie
This segment only started yielding results from late May 2021, so the revenue you see before you of ~14cr is only for a month. Next Quarter this should contribute more.
Q4 of this year or Q1 of next year is when you should see a good increase in earnings.
Why?
Their new additions towards FDF capacity will get commercialized and in effect will double the FDF earnings of Q4FY21.
Generic APIs
They are moving away from ARV to other areas like oncology, CVS and Diabetes.
Moving from one product API company to a diversified basket of APIs.
Oncology showed a robust growth.
CVS and Diabetes witnessed shipment disruptions
(my #1 risk to monitor this Q)
Synthesis, CDMO business
(the most exciting slide from their investor presentation)
550KL+ capacity is no small feat.
No pharma company is complete with continuous R&D. They spent 3.8% of Sales on R&D this Quarter.
All in all, great results. I am happy, remain invested.
Grab a cup of coffee. In this thread, I will explain:
1. What is Behavioral Finance? 2. What are biases and how do they impact 99% of investors? 3. What are different types of biases and how to overcome them?
Let's dive right in.
2/ Behavioral finance is a field that studies how psychological, human biases and emotions influence financial and investment decision-making.
3/ Humans by nature are driven by emotions and are a irrational species.
This irrationality seeps through in investing, finance and global capital markets.
Grab a cup of coffee. In this thread, I will explain:
1. What is cost of capital and WACC? 2. How does a company's capital structure impact its valuations? 3. How to code WACC as a field in screener?
Let's dive right in.
2/ Before we start to explore cost of capital, we first need to understand what is meant by capital structure of a company.
3/ Any business at a very simplified level, works in three steps
Step 1: Raise funds from various types of investors
Step 2: Use those funds to build projects that generate higher returns
Step 3: Deliver excess returns back to investors
1⃣ Provide loans to banks
2⃣ Value US Treasuries held by banks at par for collateral, even if they are currently not valued at par
3⃣ Inject USD 25B into banking system
They are calling it BTLP
Its essentially QE with a different label
It took Fed ~2 years to sell $600B and only a few days to reverse 50% of that
Just last week alone Fed bought $300B worth of assets
Current size of Fed Balance Sheet ~8.5Trillion USD
This is the MOVE index, its volatility index for Bonds, similar to what VIX is for equities
The only time when MOVE was higher than current levels, was in 2008
#AartiPharmaLabs lists today, here are some slides from my presentation at @ias_summit to help you understand the business ⤵️
The current share price is expensive, I wouldn't be a buyer at this price 🛑
D: Not an investment recommendation
@ias_summit At 315/share, the market is implying a market cap of ~2850.75cr to the company or a PE multiple of ~18x TTM earnings
@ias_summit Since, the implied valuation is towards a premium & there are large institutional holdings in Aarti Industries, expect decent amount of selling in next few weeks
On the other hand, I also believe promoters will raise stake so need to monitor this for sometime before entering